Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Acquires 5,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) Director Arnold Baskies acquired 5,000 shares of the stock in a transaction on Thursday, September 24th. The stock was acquired at an average cost of $2.76 per share, for a total transaction of $13,800.00. Following the acquisition, the director directly owned 140,572 shares in the company, valued at $387,978.72. This represents a 3.69% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Anixa Biosciences Trading Up 2.2%

NASDAQ ANIX opened at $2.85 on Wednesday. The business’s 50 day moving average is $3.21 and its two-hundred day moving average is $2.97. Anixa Biosciences Inc has a 12-month low of $2.32 and a 12-month high of $5.46. The stock has a market capitalization of $99.07 million, a price-to-earnings ratio of -8.91 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). Equities analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANIX has been the subject of several research analyst reports. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Finally, Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Investors Weigh In On Anixa Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in Anixa Biosciences in the 2nd quarter valued at approximately $559,000. GSA Capital Partners LLP acquired a new position in Anixa Biosciences during the second quarter worth $329,000. Renaissance Technologies LLC boosted its position in Anixa Biosciences by 13.6% during the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after purchasing an additional 7,300 shares in the last quarter. Kestra Advisory Services LLC boosted its position in Anixa Biosciences by 96.2% during the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock worth $132,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Anixa Biosciences in the second quarter valued at $133,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.